Glucocorticoids in the Management of Systemic Juvenile Idiopathic Arthritis
- 29 June 2013
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 15 (5) , 343-349
Abstract
Glucocorticoids have been the mainstay of treatment for many years in systemic-onset juvenile idiopathic arthritis (sJIA), causing important side effects and some difficulties in the management of this disease. Until the introduction of biologic agents, oral glucocorticoids were used to control fever and other systemic features for several months or even years if systemic manifestations persisted. Nowadays, clinicians have valid alternatives that have revolutionized the natural history of sJIA. Biologic agents, such as the interleukin-1 inhibitors anakinra and the more recent canakinumab, or the interleukin-6 inhibitor tocilizumab, have improved the prognosis of this debilitating disease. Glucocorticoids still have to be considered at the onset of disease when a non-steroidal anti-inflammatory drug therapy fails or when there are life-threatening complications such as severe anemia or pericarditis, or macrophage activation syndrome. Local (intra-articular) triamcinolone hexacetonide is the treatment of choice for arthritis limited to one joint or a few joints in patients without systemic activity. To date, there is still great heterogeneity in the management of sJIA patients, but in recent years there have been attempts to design algorithms and treatment protocols for glucocorticoids, disease-modifying anti-rheumatic drugs, and biologic agents. This review provides an overview of the current knowledge of glucocorticoid therapy in sJIA, comments on recently published recommendations, and gives practical support to the clinician for management of this disease.Keywords
This publication has 48 references indexed in Scilit:
- Long‐Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic ArthritisArthritis & Rheumatism, 2013
- Pharmacokinetics of Modified‐Release Prednisone Tablets in Healthy Subjects and Patients With Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2013
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic ArthritisNew England Journal of Medicine, 2012
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic ArthritisNew England Journal of Medicine, 2012
- Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodologyPediatric Rheumatology, 2012
- Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2012
- Systemic Arthritis in Children: A Review of Clinical Presentation and TreatmentInternational Journal of Inflammation, 2011
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals of the Rheumatic Diseases, 2011
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Systemic JIA: new developments in the understanding of the pathophysiology and therapyBest Practice & Research Clinical Rheumatology, 2009